Breast cancer, aromatase inhibitors, and bone health
Aromatase inhibitors (AIs) are a first-line therapy for postmenopausal women diagnosed with estrogen receptor-positive breast cancer. Because of the estrogen…
The development and implementation of an HBOC risk assessment protocol can decrease morbidity and mortality.
“Benign Breast Conditions: The Role of the WHNP,” will be a breakout session at the 24th Annual NPWH Premier Women’s Health Conference Oct. 13 to 16. See article for registration details.